Thomas Jefferson University

Jefferson Digital Commons
Department of Pathology, Anatomy, and Cell
Biology Faculty Papers

Department of Pathology, Anatomy, and Cell
Biology

1-20-2009

Systems-level interactions between insulin-EGF networks amplify
mitogenic signaling.
Nikolay Borisov
Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University

Edita Aksamitiene
Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University

Anatoly Kiyatkin
Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University

Stefan Legewie
Institute for Theoretical Biology, Humboldt University
Follow this and additional works at: https://jdc.jefferson.edu/pacbfp

Jan Berkhout

Department
of Other
Pathology,
Anatomy
and Cell
Biology, Thomas Jefferson University
Part of the
Medical
Specialties
Commons

Let us know how access to this document benefits you
See next page for additional authors

Recommended Citation
Borisov, Nikolay; Aksamitiene, Edita; Kiyatkin, Anatoly; Legewie, Stefan; Berkhout, Jan; Maiwald,
Thomas; Kaimachnikov, Nikolai P; Timmer, Jens; Hoek, Jan B; and Kholodenko, Boris N,
"Systems-level interactions between insulin-EGF networks amplify mitogenic signaling." (2009).
Department of Pathology, Anatomy, and Cell Biology Faculty Papers. Paper 127.
https://jdc.jefferson.edu/pacbfp/127
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Pathology, Anatomy, and Cell Biology Faculty Papers by an authorized
administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.

Authors
Nikolay Borisov, Edita Aksamitiene, Anatoly Kiyatkin, Stefan Legewie, Jan Berkhout, Thomas Maiwald,
Nikolai P Kaimachnikov, Jens Timmer, Jan B Hoek, and Boris N Kholodenko

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/pacbfp/127

Molecular Systems Biology 5; Article number 256; doi:10.1038/msb.2009.19
Citation: Molecular Systems Biology 5:256
& 2009 EMBO and Macmillan Publishers Limited All rights reserved 1744-4292/09
www.molecularsystemsbiology.com

Systems-level interactions between insulin–EGF
networks amplify mitogenic signaling
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Crosstalk mechanisms have not been studied as thoroughly as individual signaling pathways. We
exploit experimental and computational approaches to reveal how a concordant interplay between
the insulin and epidermal growth factor (EGF) signaling networks can potentiate mitogenic
signaling. In HEK293 cells, insulin is a poor activator of the Ras/ERK (extracellular signal-regulated
kinase) cascade, yet it enhances ERK activation by low EGF doses. We find that major crosstalk
mechanisms that amplify ERK signaling are localized upstream of Ras and at the Ras/Raf level.
Computational modeling unveils how critical network nodes, the adaptor proteins GAB1 and insulin
receptor substrate (IRS), Src kinase, and phosphatase SHP2, convert insulin-induced increase in the
phosphatidylinositol-3,4,5-triphosphate (PIP3) concentration into enhanced Ras/ERK activity. The
model predicts and experiments confirm that insulin-induced amplification of mitogenic signaling
is abolished by disrupting PIP3-mediated positive feedback via GAB1 and IRS. We demonstrate that
GAB1 behaves as a non-linear amplifier of mitogenic responses and insulin endows EGF signaling
with robustness to GAB1 suppression. Our results show the feasibility of using computational
models to identify key target combinations and predict complex cellular responses to a mixture of
external cues.
Molecular Systems Biology 7 April 2009; doi:10.1038/msb.2009.19
Subject Categories: simulation and data analysis; signal transduction
Keywords: computational modeling; crosstalk; epidermal growth factor receptor; insulin receptor;
networks
This is an open-access article distributed under the terms of the Creative Commons Attribution Licence,
which permits distribution and reproduction in any medium, provided the original author and source are
credited. This licence does not permit commercial exploitation or the creation of derivative works without
specific permission.

Introduction
Cells respond to a myriad of external cues using a limited
number of signaling pathways that convert multiple inputs
into diverse cellular decisions. Although individual receptors
and pathways have been extensively studied, it is not
understood how signaling networks integrate multiple cues.
The epidermal growth factor (EGF) receptor (EGFR) and the
insulin receptor (IR) belong to the family of receptors with
intrinsic tyrosine kinase activity (referred to as receptor
tyrosine kinases, RTKs), which regulate pivotal cellular
processes, including proliferation, differentiation, cell metabolism, survival, and apoptosis (Schlessinger, 2000; Taniguchi
et al, 2006). The main physiological function of insulin
signaling is metabolic, involving the control of glucose
& 2009 EMBO and Macmillan Publishers Limited

metabolism and stimulation of protein and lipid syntheses,
whereas EGF induces proliferative responses.
The EGFR and IR networks share many downstream
components. Under some conditions, EGF can evoke metabolic responses, e.g., GLUT4 translocation (Ishii et al, 1994;
Gogg and Smith, 2002), whereas insulin can be mitogenic,
especially in cancer cells (Ish-Shalom et al, 1997; Papa et al,
1997). There is evidence that insulin can enhance EGFstimulated extracellular signal-regulated kinase (ERK) activation, DNA synthesis, and cell proliferation responses (Crouch
et al, 2000; Ediger and Toews, 2000; Chong et al, 2004),
whereas growth factors, cytokines, and other hormones can
negatively regulate insulin signaling (Gual et al, 2003). Yet,
despite experimental evidence of crosstalk between insulin
and growth factor pathways, it is unknown how combined
Molecular Systems Biology 2009 1
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EGF and insulin inputs are processed into integrative cellular
response. This is at least in part due to the combinatorial
complexity of molecular interactions and a variety of feedback
and feed-forward loops, whose concerted operation is difficult
to comprehend intuitively.
Ligand binding and subsequent autophosphorylation of
tyrosine residues on the EGFR and IR triggers mobilization of
multiple adaptors, such as Src (src avian sarcoma viral
oncogene homolog) homology and collagen domain protein
(Shc), growth factor receptor binding protein 2 (Grb2), insulin
receptor substrate family members (IRS1–6, GAB1–3), and
enzymes that contain characteristic domains recognizing
receptor phosphotyrosines, such as phosphatidylinositol
3-kinase (PI3K), soluble tyrosine kinase c-Src, protein tyrosine
phosphatases (e.g., SHP2 and PTP1B) and others (White,
1998; Sebastian et al, 2006). Subsequently, EGF and insulininduced signals propagate through multiple interacting
branches, including the mitogen-activated protein kinase
(MAPK) cascade downstream of the small membraneanchored GTPase Ras and the PI3K/AKTcell survival pathway.
The flow chart in Figure 1 shows that the same key signal
transducers are activated by both EGFR and IR, either directly
or indirectly. Importantly, although either receptor can
stimulate both the Ras/ERK and PI3K/AKT pathways, the
major routes of activation are different. IR phosphorylates IRS
proteins, which are linked to the activation of Ras/ERK
pathway through binding to the Grb2–SOS complex (SOS is a
guanine nucleotide exchange factor for Ras), whereas EGFR
activates the same pathway either by direct binding of Grb2SOS or by binding and phosphorylation of Shc, which then
recruits the Grb2–SOS complex (White, 1998; Sebastian et al,
2006). Likewise, the PI3K/AKT pathway is activated by IR via
either direct or IRS-mediated recruitment of PI3K, whereas
EGFR-mediated PI3K activation occurs mainly via a more

Figure 1 Flow chart of signal propagation through the EGFR and IR signaling
networks. Solid lines with arrows show the activation or tyrosine phosphorylation
of proteins and lipids. Dotted lines represent direct protein–protein and protein–
lipid interactions. Red lines with blunt ends show inhibition.
2 Molecular Systems Biology 2009

intricate route that involves EGFR- and Src-induced phosphorylation of the Grb2-associated binder 1 (GAB1) (Rodrigues
et al, 2000; Gu and Neel, 2003; Kiyatkin et al, 2006).
There are several points of crosstalk between the EGFR
and IR signaling networks (Figure 1). Following the initial
activation of PI3K, the production of phosphatidylinositol3,4,5-triphosphate (PIP3) in the plasma membrane leads to the
membrane recruitment of GAB1 and IRS proteins through their
pleckstrin homology (PH) domains. The membrane-recruited
and subsequently tyrosine-phosphorylated GAB1 and IRS
influence the Ras/ERK and PI3K/AKT pathways in multiple
ways. They bind p85, the regulatory subunit of PI3K, and
alleviate the intrinsic inhibition of PI3K, which further
increases PIP3 production, thereby generating a positive
feedback and a crosstalk point between EGFR and IR (Ogawa
et al, 1998; Gu and Neel, 2003). Both GAB1 and IRS can recruit
Grb2–SOS, leading to Ras activation (Myers et al, 1994;
Lewitzky et al, 2001; Weng et al, 2001), or can bind the GTPaseactivating protein RasGAP, which catalyzes Ras deactivation
(Montagner et al, 2005). An important crosstalk point emerges
because of the binding of SH2 domain-containing tyrosine
protein phosphatase 2 (SHP2) to the phosphorylated GAB1
and IRS proteins, which results in both positive and negative
regulations of downstream signaling (Noguchi et al, 1994;
Yamauchi et al, 1995; Myers et al, 1998; Yart et al, 2001;
Asante-Appiah and Kennedy, 2003). Intriguingly, although
tyrosine phosphatase SHP2 negatively regulates IRS, GAB1
and PI3K/AKT signaling (Noguchi et al, 1994; Asante-Appiah
and Kennedy, 2003), it positively influences ERK activity,
which is partly explained by dephosphorylation of the specific
sites involved in RasGAP binding (Cunnick et al, 2002; Agazie
and Hayman, 2003; Montagner et al, 2005; Stoker, 2005).
Downstream targets of EGFR and IR, such as ERK, GSK3
(glycogen synthase kinase 3) or mTOR (the mammalian target
of rapamycin), feedback and phosphorylate GAB1 and IRS on
serine/threonine residues, which disable tyrosine phosphorylation at sites engaging PI3K, Grb2, RasGAP or SHP2 (Paz
et al, 1997; Gu and Neel, 2003; Johnston et al, 2003). These
negative feedback loops generate additional crosstalk points
between EGFR and IR.
Although many mechanisms of EGFR–IR crosstalk are well
characterized at the molecular level, this knowledge is
insufficient to understand cellular responses to EGF plus
insulin at the systems level, owing to the multitude of
interpathway interactions and feedback loops. This paper
brings together experimental studies of combined EGF and
insulin signaling with computational modeling of the interactive EGFR and IR networks. We show that, although in
HEK293 cells insulin by itself is a poor activator of ERK, it
greatly enhances MAPK pathway activation by physiological
EGF concentrations. The computational model elucidates the
function of feedback loops and crosstalk nodes in combined
EGF and insulin signaling. We demonstrate that synergistic
activation of the mitogenic pathway by EGF plus insulin
primarily occurs upstream of and at the Ras/Raf level. This
potentiation of Ras/ERK response is initiated by insulininduced PIP3 increase, which leads to subsequent increases in
membrane recruitment of Grb2–SOS and SHP2 by GAB1 and
IRS. The computational model unveils that insulin makes the
mitogenic EGFR signal more robust toward GAB1 knockdown.
& 2009 EMBO and Macmillan Publishers Limited
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Our results may have important ramifications for the
identification of therapeutic targets aimed at eliminating
insulin-induced amplification of mitogenic and survival
signaling stimulated by low growth factor levels in tumor cells.

Results
Building a computational model of the EGF and
insulin signaling networks
We have developed a computational model to describe in
quantitative terms how cell stimulation by EGF and insulin is
linked to the activation of Ras/ERK and PI3K/AKT pathways.
The current model stems from our previously developed EGFR
network models that were based on in vitro and in vivo
measurements of signaling kinetics. A number of EGFR signaling
model predictions were validated in our own studies (Kholodenko et al, 1999; Moehren et al, 2002; Kiyatkin et al, 2006;
Birtwistle et al, 2007) and, in addition, tested by other groups
(Schoeberl et al, 2002; Hatakeyama et al, 2003; Resat et al, 2003;
Blinov et al, 2006). This paper extends our previous models to
incorporate IR signaling and regulatory processes involved in
EGFR–IR crosstalk. However, we do not create a combinatorially
complex in silico replica of all distinct biochemical species and
interactions, which would be impractical (Borisov et al, 2005;
Hlavacek et al, 2006; Birtwistle et al, 2007). Instead, we
construct a basic, minimal model of the combined EGFR and
IR networks. The goal of this model is to provide an insight into
the mechanisms of cellular responses to combined EGF and
insulin treatment that can account for our data.
The model involves 78 variables for different molecular
species, 111 chemical reactions (processes) and more than 200
parameters. A list of reactions, rate equations and parameter
values is given in the Supplementary Table S1, and the model
SBML file is provided. For many reactions, the parameter
values are quantitatively consistent with the previously
published values, whose derivation is fully documented in
the papers by Kholodenko et al (1999), Moehren et al (2002),
and Markevich et al (2004a, b). For additional processes and
parameters that describe multi-step processes as single
reactions, Supplementary Table S1 cites the corresponding
references or indicates that the parameter value was optimized
using a training set of data (see Materials and methods).
Below, we describe the major signaling processes that are
considered and analyzed by this model.
In the model, signal transduction is initiated by ligand (EGF
or/and insulin) binding to their cognate receptors. This causes
dimerization and autophosphorylation of EGFR, or an
allosteric transition and autophosphorylation of the kinase
activation loop of the predimerized IR, which leads to
activation of the IR kinase and autophosphorylation of its
cytoplasmic domain (De Meyts and Whittaker, 2002; Sebastian
et al, 2006). The model considers that phosphorylated EGFR
can directly bind Shc, Grb2–SOS, PI3K, protein phosphatase(s)
and RasGAP (Jones et al, 2006; Sebastian et al, 2006). The
membrane recruitment of cytoplasmic SOS is critical for the
initiation of the Ras/ERK pathway by both EGFR and IR
(Medema et al, 1993; Aronheim et al, 1994; Kholodenko,
2000). Interestingly, the direct recruitment of the Grb2–SOS
complex by EGFR was shown to be a less effective route of Ras
& 2009 EMBO and Macmillan Publishers Limited

activation than the EGFR–Shc–Grb2–SOS mediated pathway
owing to the corresponding binding affinities (Ravichandran
et al, 1995; Kholodenko et al, 1999). At the membrane, SOS
catalyzes the transformation of Ras-GDP into active Ras-GTP,
whereas RasGAP catalyzes the reverse process of Ras
deactivation.
In the model, phosphorylated IR can directly associate with
IRS, PI3K, phosphatase(s), and RasGAP (Staubs et al, 1994).
The IRS family of major IR docking proteins consists of at least
six members, IRS1-6; however, the model considers only a
single ‘representative’ IRS protein. Importantly in the model,
Src is strongly activated by EGFR and more weakly by IR
(Schmelzle et al, 2006). Following initial PI3K stimulation
and production of PIP3, IRS and GAB1 bind PIP3 and get
phosphorylated by IR or EGFR/Src. Phosphorylated IRS and
GAB1 recruit cytoplasmic proteins PI3K, Grb2–SOS, SHP2, and
RasGAP to the plasma membrane, which results in additional
PIP3 production and both activatory and inhibitory regulations
of Ras activity (Myers et al, 1994; Ogawa et al, 1998; Gu and
Neel, 2003). PIP3 is converted back to phosphatidylinositol4,5-diphosphate (PIP2) by PTEN (phosphatase and tensin
homologue) (Weng et al, 2001). Although both IRS and GAB1
have multiple tyrosine phosphorylation sites, the minimal
model represents them by a single, virtual phosphorylation
site (Birtwistle et al, 2007). There are some experimental data
supporting this assumption and showing that binding of
multiple SH2 domain-containing proteins correlates with the
overall phosphorylation levels of GAB1 (Figure 4D and E
below) and IRS (Goldstein et al, 2000).
Where appropriate, we describe complex yet sequential
multi-step processes as a single, semi-mechanistic step. As
these condensed processes are sequential, our simplifications
allow the reduced model to retain the original network
topology. For instance, the activation of Raf by Ras includes
a conformational change in Raf caused by binding to Ras-GTP,
followed by the dissociation of 14-3-3 protein, dephosphorylation of inhibitory S259 and phosphorylation of activatory S338
sites (Dhillon et al, 2002). In the model, all these processes
are considered as a single partial step of Raf activation. The
complete Raf activation requires tyrosine phosphorylation by
kinases, which are thought to belong to the Src family kinases
(SFK) (Wellbrock et al, 2004). In the model, these kinases are
linked to Src activity, which is differently stimulated by EGFR
or IR. Likewise, in the absence of evidence for a distributed
mechanism of ERK kinase (MEK) activation by Raf (Kolch,
2005), we use a simplified, one-step description, whereas a
distributed mechanism of ERK activation by MEK and
deactivation by MKP3 is described as a two-step process
(Markevich et al, 2004a).
The model also incorporates and analyzes complex feedback circuitry of the EGFR and IR networks. For instance, PIP3dependent positive feedback circuits in the model involve
GAB1–PI3K and IRS–PI3K interactions (Rodrigues et al, 2000;
Johnston et al, 2003; Mattoon et al, 2004). Activated ERK
inhibits SOS (Dong et al, 1996; Fucini et al, 1999), GAB1 (Lehr
et al, 2004) and IRS (De Fea and Roth, 1997) by direct
phosphorylation. Activated mTOR mediates multiple modes of
feedback, including positive feedback to AKT and negative
feedback loops to IRS (Gual et al, 2003; Sarbassov et al, 2005).
Although AKT-induced inhibitory phosphorylation of Raf
Molecular Systems Biology 2009 3
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(Zimmermann and Moelling, 1999; Wellbrock et al, 2004) is
included in the model, we assume this inhibition to be weak in
HEK293 cells, as no noticeable MEK or ERK activation was
detected experimentally, following inhibition of AKT activity

(see Supplementary Figure S4). The current model involves
many parameters that have no analogs in our previously
published models. We used the experimental data that are
shown in Figures 2 and 3 (excluding experiments with PI3K

Figure 2 Dynamics of EGF or insulin-induced Ras-GTP, ERK and AKT activation, and GAB1 phosphorylation. The left panels show the time courses calculated
in silico and right panels show the corresponding time courses measured in HEK293 cells stimulated with insulin (Ins, 100 nM) or EGF (0.1, 1 or 20 nM) for the indicated
time intervals (min). Active GTP-bound Ras was immunoprecipitated (IP) from total cell lysates (TCL) by the agarose-conjugated Ras-binding domain (RBD) of Raf as
described in Materials and methods. Proteins from Ras-IP or TCL were separated on LDS-PAGE (4–12%), transferred to nitrocellulose membrane, and immunoblotted
(IB) with anti-Ras (A) or anti-phospho-ERK1/2 (T202/Y204), anti-phospho-AKT (S473) or anti-phospho-GAB1 (Y627) antibodies (B–D), respectively. The signal
intensities of phosphorylated ERK1/2, AKT, or GAB1 normalized against the appropriate signal of a-tubulin protein level are expressed in arbitrary units (AU). Data
shown are the mean of normalized signal intensities±s.d. from five independent experiments each performed in triplicates.
4 Molecular Systems Biology 2009
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Figure 3 Insulin amplifies EGF-induced Ras/MAPK pathway activation at low EGF doses. Comparison of the calculated in silico dynamics of Ras-GTP (A), phosphoMEK (B), phospho-ERK1/2 (C), and phospho-GAB1 (D) stimulated with EGF (0.1 or 1 nM) or EGF plus insulin (EGF þ Ins) in the absence or presence of PI3K inhibitor
wortmannin (WT) with the corresponding kinetic measurements (shown in bottom (A, B) or right (C, D) panels) carried out in HEK293 cells stimulated with EGF (0.1, 1 or
20 nM) or co-stimulated with insulin (100 nM) plus EGF ( þ or  indicate the presence or absence of the ligand). Grb2 levels serve as a loading control to show that
equal amounts of protein were loaded per lane. Representative blots are shown (n¼3). (E) HEK293 cells were pretreated with 100 nM WT ( þ ) or equivalent amounts of
solvent DMSO () for 30 min and stimulated with 0.1 nM EGF or 100 nM insulin or both ligands simultaneously for 1.5 min (left panel), 5 min (middle panel) or 15 min
(right panel). Immunoblots were analyzed for phosphorylated MEK (S217/221), ERK1/2 (T202/Y204), or AKT (S473) (representative blots on the upper part of each
panel). The ligand-induced ERK responses are expressed in arbitrary units (AU) (mean±s.d., n¼7).

inhibitor) as a training data set to obtain reasonable fit
between the model simulations and data by manually varying
the parameter values (see Supplementary Table S1). However,
when parameters were fitted, their upper and lower bounds
were in agreement with experimental observations for similar
reaction types. In addition, reaction rates were always
constrained not to be faster than the diffusion limit.
& 2009 EMBO and Macmillan Publishers Limited

Dose dependence of responses to EGF and insulin
Steady-state plasma concentrations of EGF are reported to be
in the range of 0.05–0.2 nM, which is much lower than the
concentration range commonly used in the studies on isolated
cells (Jansson et al, 1993; Lemos-Gonzalez et al, 2007). For
HEK293 cells, which express endogenous EGFR and IR, we
Molecular Systems Biology 2009 5
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Figure 3

Continued.

measured both EGF and insulin dose dependencies. We
found that half-maximal ERK activation is attained at about
0.1–0.2 nM EGF (Supplementary Figure S1A). Half-maximal
phosphorylation of IR was reached at about 50–100 nM
insulin, which was sufficient to saturate ERK activation
(Supplementary Figure S1B). To exclude crosstalk at the
receptor level, we measured EGFR activation by insulin (and
vice versa), and found that neither EGF transactivated IR, nor
insulin transactivated EGFR (Supplementary Figure S2A).
Although EGF was reported to induce phosphorylation of IRS
proteins in A431 cells that express high levels of EGFR (Fujioka
et al, 2001), EGF could not induce significant IRS phosphorylation in HEK293 cells (Supplementary Figure S2B), which is
consistent with other studies (Kadowaki et al, 1987). By
contrast, insulin treatment resulted in potent phosphorylation
of IRS1 at Y612 (Supplementary Figure S2B), which is one of
the nine putative PI3K binding sites (White, 1998). Robust
phosphorylation of these sites by IR correlates with a stronger
activation of the PI3K target AKT by insulin than by EGF,
6 Molecular Systems Biology 2009

although the basal level of AKT phosphorylation in HEK293
cells is significant (Supplementary Figure S2B). However,
even at saturating concentrations, insulin is a much weaker
activator of ERK than physiological, low EGF (Supplementary
Figure S2B), which is also supported by independent
observations (Weng et al, 2001).

Signaling dynamics of EGF and insulin-induced
responses
To analyze the signaling dynamics, we measured experimentally and simulated in silico the time course of activation of
Ras/ERK and PI3K/AKT pathways stimulated by step changes
in the EGF and insulin concentrations. First, cells were
stimulated with 100 nM insulin or with several EGF concentrations that ranged from low concentrations of 0.1 nM to
saturating concentrations of 20 nM (Figure 2). Both the
experimental data and simulations showed that the activation
& 2009 EMBO and Macmillan Publishers Limited
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of the Ras/ERK and PI3K/AKT pathways by persistent EGF or
insulin stimulation was transient (Figure 2 and Supplementary
Figure S3). The model explains this transient behavior by
multiple negative feedback regulations mediated by ERK, AKT
and mTOR. In fact, disruption of negative feedback loops in
silico transforms transient Ras/ERK and PI3K/AKT pathway
responses into sustained responses (Supplementary Figure S5).
Our data demonstrate weak Ras and ERK (Figure 2A and B)
activation by insulin compared with EGF. The model provides
several arguments to explain these observations, which
involve signaling processes both upstream and downstream
of Ras. First, IR binds and phosphorylates Shc with very low
efficacy compared with EGFR ((Paz et al, 1996, 1997; Weng
et al, 2001) and Supplementary Figure S2B), whereas in EGF
signaling, the Shc-dependent pathways contribute substantially to the Grb2–SOS membrane recruitment and subsequent
Ras activation (Kholodenko et al, 1999). Second, IRS1-6
docking proteins, when phosphorylated by IR, bind preferably
PI3K, whereas their binding to Grb2–SOS is weak. Therefore,
IRS phosphorylation does not lead to significant Ras activation
in the model (Sasaoka et al, 1996; Fucini et al, 1999). Third, IR
is a much weaker stimulator of Src activity than EGFR
(Schmelzle et al, 2006), which has the following ramifications
in the model: (a) although insulin triggers the PIP3-mediated
membrane recruitment of GAB1, the phospho-GAB1 level
remains much lower than this level for EGF stimulation, when
GAB1 is phosphorylated by both EGFR and Src (see Figure 2D,
left and right panels compare the model simulations and data);
(b) the lower level of GAB1 phosphorylation by insulin results
in less effective Grb2–SOS recruitment and Ras activation
(Figure 2A); and (c) finally, downstream of Ras in the model,
full Raf activation requires Src activity, which is weaker for
insulin than for EGF. Although a higher AKT activation by
insulin than by EGF may contribute to additional Raf
inhibition, our data suggest that this inhibition is insignificant
in HEK293 cells (Supplementary Figure S4). Overall, the
simulations qualitatively agree with the data (Figure 2) for a
wide range of parameter values for the proposed regulatory
structure of the model.

Insulin potentiates MAPK responses to
physiological EGF concentrations
Our experimental and simulation results show that costimulation by low, physiological EGF (0.1 nM) and insulin
synergistically activates the Ras/ERK pathway (Figure 3A–C,
quantitation of the blots shown in Figure 3A–C is presented in
Supplementary Figure S6A–C). Figure 3E demonstrates that at
1.5 min (left panel) and 15 min (right panel) following costimulation with insulin and EGF, the concentration of active
ERK is 2.57±0.44 and 1.4±0.1 times greater, respectively,
than the sum of the active ERK levels observed with each
ligand (this synergistic increase is statistically significant,
Po0.01, n¼5). Importantly, the synergy effect is not a
consequence of additional activation of EGFR and/or IR by
co-stimulation with two ligands (Supplementary Figure S2A).
Neither can it be explained by activation of insulin-like growth
factor receptor-1 (IGF-1R) by insulin. Although 100 nM insulin
weakly activates IGF-1 receptor at 1.5 min (Supplementary
& 2009 EMBO and Macmillan Publishers Limited

Figure S2C), 10 nM insulin, which does not transactivate
IGF-1R (Supplementary Figure S2C), induces the comparable
synergistic effect when combined with 0.1 or 1 nM EGF
(Supplementary Figure S2D). When ERK activation is maximal, the synergy becomes insignificant (P40.05) for any
studied EGF dose (Figure 3C and E). Furthermore, the
synergistic activation of ERK is less pronounced at higher
EGF (1 nM, Figure 3C), and disappears at saturating EGF
(20 nM, Supplementary Figure S7).
One group of crosstalk interactions that facilitate the ERK
response is located upstream of Ras. These interactions affect
multiple Ras activation and deactivation routes involving the
adaptor proteins GAB1 and IRS and the protein phosphatase
SHP2. In the model, co-stimulation of cells by EGF and insulin
increases the amount of PIP3 produced by PI3K (relative to EGF
stimulation alone) and further facilitates the GAB1 membrane
recruitment and its subsequent tyrosine phosphorylation
(Figure 3D, left and middle panels). An increase in membrane-bound phospho-GAB1 is corroborated by our data and it
is more appreciable at physiological EGF levels (Supplementary Figure S8B, Figure 3D, right panel, and Supplementary
Figure S8A).
An increase in the phosphorylation level of membranebound GAB1 promotes Grb2–SOS binding, increasing the SOS
concentration in close proximity to Ras (Kholodenko et al,
2000). At the same time, this gain in phospho-GAB1 also
increases the amount of RasGAP (Ras deactivator) and the
phosphatase SHP2 bound to GAB1. In the model, this
phosphatase negatively regulates the level of phosphorylated
receptors, IRS, and GAB1; yet it has the pronounced positive
effect on Ras activation, as we showed using a specific SHP2
inhbitor, NSC-87877 (Supplementary Figure S9A). This
positive effect is related to the formation of the GAB1–SHP2
and IRS–SHP2 complexes in close proximity to the plasma
membrane and subsequent dephosphorylation of the docking
sites on EGFR, IR, GAB1, and IRS, which are involved in
RasGAP binding. Thus, SHP2 has an essential role in inhibiting
RasGAP-catalyzed Ras deactivation, only if there is a strong
activatory signal to Ras arising from EGF co-stimulation,
whereas the IRS–SHP2 complexes cannot effectively activate
Ras on their own. Simulations predict that the net result of
these insulin plus EGF-induced interactions is an increase in
positive signaling and decrease in negative signaling to Ras.
This amplifies the Ras-GTP level, which is corroborated by the
experimental data (Figure 3A).
The second group of crosstalk interactions occurs downstream of Ras and involves processes with positive and
negative effects on ERK responses. In the model, at any given
Ras-GTP load, the simultaneous exposure to insulin and EGF
increases Raf activity relative to insulin alone, owing to EGFinduced stimulation of SFK, which further activates Raf. At the
same time, an increase in AKT activity brought about by
simultaneous stimulation with insulin and EGF should
negatively influence Raf. Yet, the experimental data (Supplementary Figure S4) and simulations suggest that in HEK293
cells the negative influence of AKT on Raf is negligible in
comparison with increased Raf activation, owing to increases
in Src and Ras activities. Thus, the net effect of insulin-EGF
co-stimulation on MEK and ERK activation is positive
(Figure 3B and C).
Molecular Systems Biology 2009 7
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PI3K inhibition suppresses insulin–EGF synergy
in Ras/ERK responses

GAB1 complexes with Grb2, SHP2 and PI3K
measured by immunoprecipitation analysis

To test the model predictions on the PIP3/GAB1-mediated
signaling routes that result in synergistic Ras/MAPK activation
by insulin and EGF, the cells were pretreated with the PI3K
inhibitor wortmannin (WT). As expected, 100 nM WT
prevented AKT phosphorylation in response to insulin and
EGF (Figure 3E). By contrast, tyrosine phosphorylation of
EGFR, IR and Shc was not affected by PI3K inhibition
(Supplementary Figure S10 and Kiyatkin et al, 2006).
Although the model is trained to describe the experimental
time-series data for unperturbed cells, simulations of pharmacological interventions, such as inhibition of network nodes
and small interfering RNA (siRNA) experiments (see below),
were not fitted to the data. Rather, the model predictions are
merely compared with the experimental data. The simulations
and data suggest that EGF-induced MEK/ERK activation is
inhibited by WT due to the disruption of GAB1–PI3K positive
feedback. The model predicts that owing to inhibition of the
GAB1 and IRS–SHP2 membrane recruitment, WT suppresses
synergistic amplification of Ras-GTP/MEK/ERK responses,
which is supported by our experimental data (Figure 3A–C and
E). The model simulations suggest that although WT disrupts
the EGF–insulin synergy, the maximal activation of MEK and
ERK remains significant, following 5-min stimulation with
EGF or EGF plus insulin. The data presented in Figure 3E
(middle panel) validate the model prediction and also show
that insulin is unable to enhance MEK and ERK when PI3K is
inhibited (Figure 3E, all panels). The agreement between the
model predictions and experimental observations substantiates the computational model.

Quantitative data on the dynamics of protein–protein complexes can further validate the model and provide insight into
mechanisms of integrative cellular responses to insulin–EGF
co-stimulation. As the data (Figure 3D and Supplementary
Figure S8) suggest that GAB1 is one of the key mediators of
insulin–EGF crosstalk, we determined GAB1 interactions with
other network nodes. Although it is not immediately obvious,
the simulations predict that following co-stimulation with
insulin and EGF, the amount of GAB1-bound PI3K will increase
(compared with EGF stimulation) only on a short time scale
(Figure 4A, blue dashed lines versus green dotted lines),
whereas the post-peak concentration of GAB1-bound PI3K will
decrease owing to dephosphorylation of GAB1 phosphotyrosines by GAB1-bound SHP2 and the competitive recruitment
of PI3K by phosphorylated IRS. To test this prediction, the
binding of PI3K and SHP2 to GAB1 and of PI3K to IRS4 (the
major IRS protein in these cells (Fantin et al, 1998)) was
measured by immunoprecipitation analysis following stimulation of HEK293 cells with EGF, insulin and their combination.
The data confirm that insulin–EGF co-stimulation increased
the PI3K–GAB1 complex concentration at 30 s and 1.5 min,
whereas the post-peak levels were decreased compared with
EGF only stimulation, in agreement with in silico predictions
(Figure 4A, right panel). At 3 min of stimulation with insulin
and EGF, the data show robust PI3K–IRS binding response and
decreased PI3K–GAB1 binding, compared with EGF alone
(Figure 4B). The predicted increase in GAB1-bound Grb2
(Figure 4A, solid versus dash–dotted lines) and SHP2
(Figure 4C) correlates with an increase in the total level of

Figure 4 Association of Grb2, PI3K, or SHP2 with GAB1 in response to EGF, insulin, or their combination. (A) The left and middle panels show simulated dynamics of
GAB1-containing complexes (scales on the Y axis are different). The right panel shows quantitation of p85–PI3K in GAB1-IP (see Materials and methods). (B) HEK293
cells were stimulated with 100 nM insulin and/or 1 nM EGF for 1.5 min. p85–PI3K–IP was analyzed for IRS4, GAB1, or p85–PI3K proteins. (C) Modeling predictions of
relative SHP2 levels in GAB1-IP at 1.5 min after stimulation with 100 nM insulin and/or 0.1 and 1 nM EGF. (D) HEK293 cells were stimulated with 100 nM insulin and/or
0.1, 1, and 20 nM EGF for 1.5 min. GAB1-IP was analyzed for total phosphotyrosines (pY20), Grb2, SHP2, or GAB1 proteins. (E) HEK293 cells were pretreated with
100 nM WT ( þ ) or equivalent amounts of solvent DMSO () for 30 min and stimulated with 1 nM EGF for 3 min. GAB1-IP was analyzed for total phosphotyrosines
(pY20), Grb2, SHP2, p85–PI3K, or GAB1 proteins. Representative blots are shown in each panel (n¼3).
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GAB1 tyrosine phosphorylation (Figures 3D and 4E) and is
supported by the data shown in Figure 4D for 1.5-min
stimulation (quantitation of the blots shown in Figure 4B, D
and E is presented in Supplementary Figure S11A–C).
As WT disrupts GAB1–PI3K positive feedback, the total
GAB1 phosphorylation level and the concentrations of GAB1bound Grb2, SHP2, and PI3K decrease dramatically in WTtreated cells (Figure 4E). We conclude that the loss of insulin–
EGF synergy caused by WT arises from the loss of the GAB1mediated membrane recruitment of signaling molecules. The
following section presents direct in silico and experimental
analyses of GAB1 depletion.

Computational predictions and experimental
validation of the GAB1, SHP2, and Src control
of ERK responses to EGF and insulin
We have recently shown that RNA interference (RNAi)mediated GAB1 depletion can reduce the peak amplitude and

decrease the duration of ERK activation (Kiyatkin et al, 2006).
These findings are also supported by independent data (Meng
et al, 2005). To get further insight into the mechanisms of
crosstalk, we simulated the dynamics of ERK responses to EGF
versus EGF plus insulin in cells where the GAB1 protein level
was held at different levels with respect to control (Figure 5A).
As expected, GAB1 suppression reduces the phospho-ERK
level, and its decline is more pronounced for EGF (Figure 5A,
left panel) than for EGF plus insulin (Figure 5A, right panel).
To test the model, HEK293 cells were transfected with siRNA
against human GAB1, resulting in B75% reduced GAB1
protein level relative to control (non-targeting siRNA-transfected cells) (Figure 5C, quantitation of blots is shown in
Supplementary Figure S11D). The phospho-ERK levels measured at 1.5 min following stimulation (Figure 5C) are
consistent with the simulations (Figure 5B, left). These results
confirm the in silico prediction of the larger influence of GAB1
depletion on EGF- rather than on EGF plus insulin-induced
ERK phosphorylation.

Figure 5 Effects of GAB1 depletion on ERK activation induced by EGF, insulin, or their combination. (A) Computational analysis of ERK activation kinetics in response
to 0.1 nM EGF in the absence (left panel) or presence (right panel) of 100 nM insulin at the indicated levels of GAB1 protein. Time courses are shown for 225 nM (control;
black—solid line), 150 nM (red—long dash line), 115 nM (dark yellow—short–long–short dash line), 95 nM (dark pink—long–short–short dash line), 75 nM (green—short
dash line), 37.5 nM (blue—dash–dot line), 15.0 nM (cyan—dash–dot–dot line), 1.5 nM (gray—long–short dash line) and 0 nM (dark red—dotted line) GAB1
concentrations. (B) Simulated dependences of phospho-ERK level at 1.8 min (left panel) and maximal phospho-ERK level (right panel) on the GAB1 abundance for cells
stimulated with 0.1 nM EGF in the presence (red solid line) or absence (blue dashed line) of 100 nM insulin. (C) HEK293 cells transfected with specific siRNA against
GAB1 ( þ ) or non-targeting siRNA () were stimulated with 100 nM insulin and/or 1 nM EGF for 1.5 min. Immunoblots were analyzed for phosphorylated ERK1/2 (T202/
Y204) or GAB1 (Y627). GAB1 protein levels demonstrate the efficacy of GAB1 suppression. GAPDH was used as a loading control. Representative blot (left panel) and
the bar graph of respective numerical values (right panel) are shown.
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The computational results unveil that insulin endows
the mitogenic EGFR pathway with increased robustness
towards GAB1 downregulation. The simulations show
that for EGF plus insulin stimulation, the peak level of
phospho-ERK decreases only slightly with GAB1 depletion,
whereas for EGF-induced ERK activation, the peak level
decreases significantly (Figure 5B, right panel). The difference
between EGF- and insulin plus EGF-induced maximal
ERK activity is larger in cells with low GAB1 expression than
in cells with high GAB1 expression (Figure 5B, right panel),
although the absolute value of the peak ERK response
is greater for larger GAB1 abundance (Figure 5A). This
dependence of the gain in ERK signaling on the GAB1
abundance resembles the behavior of a non-linear amplifier,
in which a change in the input does not produce a proportional
change in the output. Moreover, the GAB1-mediated amplification of ERK signaling depends on the particular cellular
context.
The model predicts that expression of GAB1 PH domain
deletion mutant, which is unable to bind PIP3, affects ERK
activation in a similar manner as GAB1 knockdown (Supplementary Figure S12A and Figure 5A, left panel). Likewise, costimulation with EGF and insulin makes ERK activation less
sensitive to such GAB1 mutation (Supplementary Figure S12A
and Figure 5A, right panel). The effects of mutant GAB1
expression or GAB1 suppression differ from the inhibition of
PIP3 production by wortmannin (Figure 3C and E). When PIP3
is present in the membrane, but GAB1 is depleted or mutated,
PIP3 facilitates the formation of PIP3–IRS–SHP2 complexes,
which partially compensate the lack of PIP3–GAB1–Grb2–SOS
and PIP3–GAB1–SHP2 complexes by IRS–SHP2-dependent
suppression of RasGAP signaling. The simulations show that
when IRS–SHP2 interactions are disrupted, synergistic increase in ERK activity by EGF plus insulin co-stimulation can
be observed before, but not after the time when ERK reaches its
peak activity (Supplementary Figure S12B). Disruption of
GAB1–SHP2 interactions substantially decreases the duration
of ERK signaling induced by EGF, while the insulin plus EGF
synergy is observed (Supplementary Figure S12C). The effects
of other perturbations to the system are presented in
Supplementary Figures S12D and S12E. The lack of GAB1
phosphorylation by EGFR leads to phospho-ERK changes that
are qualitatively similar to the changes induced by the lack of
GAB1–PIP3 binding (Supplementary Figure S12D), whereas
the effects of IRS depletion are qualitatively similar to the
effects of disruption of IRS–SHP2 interactions (Supplementary
Figure S12E).
The phospho-ERK levels measured in Src-depleted cells
(Supplementary Figure S13A) agree reasonably well with the
corresponding model predictions (Supplementary Figure
S13C). Neither EGFR nor IR autophosphorylation levels were
affected by Src downregulation (data not shown). Moreover,
we found that RNAi-mediated suppression of Src in HEK293
cells led to a decrease in GAB1 phosphorylation that was more
pronounced for EGF than for insulin. Considering a substantial
Src contribution to GAB1 phosphorylation under various
conditions (Nishida et al, 1999; Bisotto and Fixman, 2001;
Chan et al, 2003; Jin et al, 2005), the model explains this
observation by the fact that Src is preferably activated by EGFR
and not by IR.
10 Molecular Systems Biology 2009

At the same time, the model predicts that the influence of
SHP2 activity inhibition on ERK phosphorylation will be
pronounced after 5 or more minutes following the onset of
stimulation (Supplementary Figure S13D), whereas the
experimental data show that this effect is already substantial
at 1.5 min after stimulation (Supplementary Figure S13B). This
shows the limitations of the minimal model, which should be
improved in the future studies.

Discussion
Physiological stimuli never act in isolation, and cells in the
body are often exposed to insulin and EGF at the same time.
Receptors, adaptors, and enzymes involved in insulin and EGF
signaling are relatively well-described and form complex
networks with intricate interaction circuitry. Downstream of
IR and EGFR, these networks significantly overlap. This paper
employs a combined experimental and computational approach to address the question of how multiple crosstalk
mechanisms in the IR and EGFR networks operate together in a
cell-dependent context.
The dynamics of ERK activation depends on a complex
interplay of a multitude of regulatory signals and interactions
induced by combined insulin and EGF stimulation. Using only
qualitative arguments, it is almost impossible to predict the
ERK dynamics that results from multiple non-linear interactions and feedback loops, and a testable computational model
helps us provide insights into key causative relationships
(Kholodenko, 2006). Previous experimental studies indicated
that insulin enhances growth-factor-dependent mitogenesis,
but the molecular mechanisms remained obscure, as insulin
treatment alone fails to induce mitogenesis in most cell types.
Using ERK phosphorylation as a marker for mitogenic
signaling, we show that insulin leads to the co-localization
of mitogenic signaling intermediates at the plasma membrane,
whereas EGF-dependent processes contribute to tyrosine
phosphorylation of key intermediates. Insulin thereby indirectly boosts signaling events induced by physiological, low
EGF doses, despite insulin itself being unable to directly trigger
mitogenic signaling. Our results suggest that the regulation
of PI3K signaling by non-mitogenic stimuli might be an
important means to control the key quantitative aspects of
growth-factor-induced MAPK signaling (e.g., signal amplitude
and duration).
Our results suggest that co-stimulation with low, physiological EGF doses and insulin endows the mitogenic EGFR
pathway with more sustained ERK signaling. Early observations showed that the duration of ERK activation is crucial for
cell fate decisions (Marshall, 1995). In these classical experiments, PC12 cells proliferated after transient ERK activation by
EGF, but differentiated after more sustained ERK activation by
the nerve growth factor. Subsequent work revealed that the
duration of ERK activation is sensed by a network of
immediate early genes, including the transcription factor
c-Fos (Murphy et al, 2002), while the differential timing of
ERK signaling is explained by subtle alterations in signaling
circuits, induced by distinct ligands (Kholodenko, 2007).
Crosstalk interactions in receptor-induced Ras-MAPK
signaling typically occur upstream or at the level of Raf
& 2009 EMBO and Macmillan Publishers Limited
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(Katz et al, 2007). Our computational and experimental results
also confirm that the major interactions involved in insulin–
EGF crosstalk and responsible for amplification of ERK
signaling in HEK293 cells operate at the level of protein
adaptors, such as GAB1 and IRS, and at the Ras/Raf
level. However, in other cellular systems PI3K-induced crosstalk interactions can occur downstream of Ras/Raf. For
instance, PIP3 generated by PI3K enables Rac activation.
Subsequently, Rac activates PAK, which in turn stimulates Raf
by S338 phosphorylation and MEK by S298 phosphorylation
(Chaudhary et al, 2000; Xiang et al, 2002). An alternative
pathway of PIP3-dependent ERK activation involves
phosphoinositide-dependent kinase-1 (PDK1), a target of
PI3K, which can activate MEK directly (Sato et al, 2004)
and ERK indirectly through the activation of certain PKC
isoforms (Myers et al, 1996; Schonwasser et al, 1998; Newton,
2003), although it has been reported that PKCs are not
involved in EGF-induced ERK activation (Xu et al, 2002; Robin
et al, 2004). However, in HEK293 cells, we found that the
inhibition of c-Raf by GW-5074 eliminated MEK and ERK
activities (Supplementary Figure S14), which supports the
conclusion that major insulin–EGF crosstalk mechanisms to
amplify ERK signaling are localized upstream of Ras and at the
Ras/Raf level.

The model analyzed interactions that involve five key
network nodes, the adaptor proteins GAB1 and IRS, PI3K/PIP3,
soluble tyrosine kinase Src and protein tyrosine phosphatase
SHP2, which are all localized upstream of MEK/ERK. Together,
these nodes contribute to the amplification of ERK signaling in
the context of multiple interactions, which involve insulin and
EGFRs, Grb2–SOS, RasGAP, as well as positive and negative
feedback controls from downstream targets of insulin and EGF.
The model explains how the network structures, which
involve (i) GAB1-mediated insulin and EGF coincidence
detection, (ii) coherent feed-forward loop from EGFR to Raf
via Src, and (iii) multiple positive (PI3K–PIP3–GAB1–PI3K)
and negative (ERK–GAB1, ERK–SOS, mTOR–IRS) feedback
loops contribute to the control of insulin plus EGF signaling
(a network motif where an initial input signal (A) induces an
intermediate input signal (B), and both the initial and
intermediate inputs are needed to generate the final output
(C), is referred as a coherent feed-forward loop (Mangan et al,
2003)). The simplified scheme shown in Figure 6 illustrates
how insulin enhances EGF-induced mitogenesis through two
partially redundant and compensating signaling branches via
IRS and GAB1. The goal of our computational model is to
predict and explain a large number of diverse patterns of
signaling dynamics obtained from our own experiments and

Figure 6 Mechanisms of insulin–EGF signal integration. (A) Weak ERK activation in response to insulin. IR is a strong activator of PI3K signaling, and insulin
stimulation induces pronounced adaptor recruitment to the membrane (GAB1-PIP3-GAB1; IRS-PIP3-IRS). The membrane-associated IRS proteins (but not GAB1)
are the preferred substrates of the IR kinase (PIP3-IRS-PIP3-pIRS). However, phosphorylated IRS proteins do not effectively recruit Ras activators, such as Grb2–
SOS, implying that insulin is a weak activator of ERK signaling. (B) ERK activation in response to physiological EGF doses. Active EGFR phosphorylates the membraneassociated GAB1 (PIP3-GAB1-PIP3-pGAB1), which in turn efficiently recruits Grb2–SOS and SHP2, and thereby activates Ras-MAPK signaling (for simplicity, the
Shc-dependent pathway of EGFR-induced MAPK activation is not shown). However, ERK phosphorylation induced by low doses of EGF may remain suboptimal, as the
GAB1 recruitment to the membrane is submaximal and highly transient (GAB1-PIP3-GAB1). GAB1 phosphorylation and Raf activation are enhanced by EGFRinduced Src kinase activity. (C) ERK activation can increase upon insulin and EGF co-stimulation. Synergistic ERK activation predominantly arises from coincidence
detection of insulin and EGF stimuli at the level of GAB1; the GAB1 adaptor is massively recruited to the membrane by IR signaling (GAB1-PIP3-GAB1) and
subsequently phosphorylated by EGFR and active Src (PIP3-GAB1-PIP3-pGAB1). The relative activities of the processes are illustrated by the boldness of the arrows.
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literature data. We applied in silico perturbations to our model
and, wherever possible, verified the predicted temporal
dynamics in vivo. Our strategy is similar to the so-called
pattern-oriented modeling, in which a large number of
quantitative and also qualitative patterns help us exclude
models that are too simple in structure or too uncertain
experimentally (Grimm et al, 2005).
We tested the model by using perturbations, including
different ligand concentrations, specific inhibitors, and RNAimediated suppression of key protein levels. These perturbations corresponded to single-parameter changes, which
represent the greatest challenge for any model, because a
multitude of temporal patterns have to be described without
changes in the rate constants. Our model generated qualitative
predictions of the temporal dynamics for diverse cellular
responses. In particular, downregulation of GAB1 and Src
expression levels using siRNA, or inhibition of PI3K resulted in
a significant decrease in synergistic ERK activation by insulin
plus EGF. The simulated ERK dynamics in cells with different
GAB1 expression (Figure 5A and B) suggest that insulin
significantly increases robustness of ERK activation to GAB1
downregulation. The experimental data for GAB1-depleted
HEK293 cells demonstrate a significantly larger decrease in the
ERK active fraction for EGF than for EGF plus insulin,
supporting the modeling results (Figure 5C).
Yet, the systems biology approach, while revealing a critical
role of GAB1, also points to the fact that this adaptor is just one
of several critical players in a complex set of interactions that
generate crosstalk between the EGFR and IR networks. Despite
the fact that RNAi-mediated knockdown of GAB1 expression
significantly decreases ERK signaling (Figure 5C), the downregulation of additional critical nodes is required to uncouple
and completely suppress insulin and EGF-induced Ras/ERK
activation. Overall, the analysis presented here demonstrates
the feasibility of using computational models to identify
critical combinations of therapeutic targets and predict
their effects on complex cellular responses to concurrent
external cues.

from Calbiochem) and GW-5074 (Tocris Biosciences) were dissolved in
DMSO and used at indicated concentrations. Annealed, desalted GAB1
and c-Src siGENOME SMARTpool siRNAs and siCONTROL NonTargeting siRNA Pool were from Dharmacon. siRNA stock solution
was prepared according to the manufacturer’s instructions and stored
at 801C. Other chemical reagents were from Fisher Scientific.

Cell culture and transfection
HEK293 (ATCC No. CRL-1573) were cultured in DMEM/F-12 (GIBCO)
supplemented with 10% FBS and penicillin–streptomycin solution
(Mediatech). The protocol of RNAi-mediated transient gene silencing
using synthetic siRNA was described previously (Kiyatkin et al, 2006).

Cell stimulation and protein extraction
For ligand-response studies, the cells were starved from 12 to 16 h in
FBS-free medium and stimulated with the indicated ligand concentrations. Preparation of total cell lysates and subcellular fractionation for
signaling analysis was performed as described previously (Kiyatkin
et al, 2006).

Protein immunoprecipitation
50 ml of recombinant protein A–Sepharose 4B (Sigma-Aldrich) 50%
beads slurry was preincubated with the indicated primary antibody
(8 mg) while gently mixing for 2 h at room temperature. The beads were
incubated with 500 mg of total lysate protein for 4 h at 41C. After the
incubation, the beads were washed twice with ice-cold IP buffer
(20 mM HEPES (pH 7.4), 150 mM NaCl, 0.1% Triton-X and 10%
glycerol) and once with PBS. The proteins were eluted in NuPAGE LDS
Sample Buffer (25% 4  NuPAGE LDS þ 10% 10  NuPAGE Sample
Reducing Agent þ 65% PBS), heated for 5 min at 751C and spun
down.

Ras activation assay
Active (GTP-bound) Ras from 500 mg total cell lysates was captured
with 30 ml of Raf-1 Ras binding domains (RBD) bound to glutathioneagarose beads (Millipore) for 3 h at 41C. Protein complexes were
collected by brief centrifugation and washed three times with ice-cold
IP buffer supplemented with 10 mM MgCl2. Ras-GTP was released from
agarose beads with NuPAGE LDS sample buffer.
Electrophoresis and immunoblotting procedures were conducted
according to the methods described in Aksamitiene et al (2007).

Materials and methods
Antibodies
Rabbit anti-phospho-MEK (S217/S221, anti-phospho-Shc (Y317), antiIGF-1 receptor b (all from Cell Signaling)), anti-phospho-IR b (Y1162/
1163), anti-GRB2 (C-23), anti-GAB1 (H-198), anti-phospho-GAB1
(Y627), anti-SH-PTP2 (C-18) (all from Santa Cruz Biotechnology),
anti-phospho-EGFR (Y1173), anti-phospho-IRS1 (Y612) (BD Biosciences), anti-PI3K–p85 a, anti-GAB1 (CT) (all from Millipore); mouse
anti-phospho-ERK1/2 (T202/185 and Y204/187), anti-phospho-AKT1
(S473) (587F11) (both from Cell Signaling), anti-a-tubulin (DM1A),
anti-Src (GD11) (both from Millipore), anti-Ras (BD Biosciences), antiglyceraldehyde-3-phosphate dehydrogenase (GAPDH) (6C5) (Chemicon) and anti-phosphotyrosine (pY20) (BioLegend). Secondary horse
anti-mouse HRP-linked IgG antibodies were from Cell Signaling, HRPconjugated ImmunoPure goat anti-rabbit IgG antibodies were from
Pierce. HRP-conjugated Protein A was from Millipore.

Other reagents
Human recombinant EGF and IGF-1 were from PeproTech, and insulin
was from SIGMA. Wortmannin (WT, PI3K inhibitor) (Cell Signaling),
NSC-87877 (SHP1/2 inhibitor), AKT-VIII (AKT 1/2/3 inhibitor) (both
12 Molecular Systems Biology 2009

Data evaluation
Chemiluminescence signals from immunoreactive bands were detected on a KODAK Image Station 440CF after treatment with a working
solution of SuperSignal West Dura Extended Duration Substrate
(Pierce Biotechnology) and quantified using KODAK Digital Science
software (Kodak Scientific Imaging Systems). To enable comparison,
the capture times and number of frames were set equal for each
separately exposed membrane, or the whole membranes were exposed
simultaneously. Results were plotted and statistically analyzed using
SigmaPlot and Microsoft Excel software.

Computational modeling analysis
Numerical integration was performed using Dbsolve and PottersWeel.
Dbsolve (Goryanin et al, 1999) is based on numerical techniques,
developed by Khibnik et al (1993). The program files are freely
available together with the model SBML file. Ranges of kinetic
parameters were constrained based on the literature data and in vivo
measurements of the signaling kinetic. The list of the quantitative
parameters is presented in Supplementary Table S1, which documents
how these parameters were determined. The parameter values marked
‘fitted’ were varied manually within the upper and lower bounds taken
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from the experiment to describe a training data set, which includes the
experimental time courses in Figures 2 and 3 obtained for an
unperturbed HEK293 system. The simulations of the perturbation
results, such as inhibition of PI3K, SHP2 and EGFR, and GAB1, IRS or
Src depletion, were not fitted to the data. Rather, the model predictions
were merely compared with the experimental data.

Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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